Holen Sie sich die Stockscreener-App
1.25
8.70%
0.10
Handel nachbörslich:
1.23
-0.02
-1.60%
Schlusskurs vom Vortag:
$1.15
Offen:
$1.21
24-Stunden-Volumen:
681.66K
Relative Volume:
3.38
Marktkapitalisierung:
$58.62M
Einnahmen:
$10.85M
Nettoeinkommen (Verlust:
$-51.31M
KGV:
-1.6961
EPS:
-0.737
Netto-Cashflow:
$-36.77M
1W Leistung:
+6.84%
1M Leistung:
-3.10%
6M Leistung:
-23.31%
1J Leistung:
-51.92%
1-Tages-Spanne:
$1.16
$1.2897
1-Wochen-Bereich:
$1.02
$1.2897
52-Wochen-Spanne:
$1.02
$2.9319
InspireMD Inc. Stock (NSPR) Company Profile
Firmenname
InspireMD Inc.
Sektor
Branche
Telefon
972 3 6917691
Adresse
4 Menorat Hamaor Street, Tel Aviv
Compare NSPR vs ABT, SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NSPR
InspireMD Inc.
|
1.25 | 53.93M | 10.85M | -51.31M | -36.77M | -0.737 |
ABT
Abbott Laboratories
|
82.56 | 146.87B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
282.58 | 109.33B | 25.27B | 3.34B | 4.57B | 8.6358 |
MDT
Medtronic Plc
|
74.54 | 97.77B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
53.37 | 80.16B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
77.17 | 46.04B | 6.30B | 1.07B | 1.09B | 1.8406 |
InspireMD Inc. Stock (NSPR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-02 | Eingeleitet | Maxim Group | Buy |
| 2016-01-07 | Eingeleitet | Rodman & Renshaw | Buy |
| 2015-03-13 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2013-11-26 | Eingeleitet | Oppenheimer | Outperform |
InspireMD Inc. Aktie (NSPR) Neueste Nachrichten
InspireMD Balances Fast Growth With U.S. Setback - TipRanks
MSN Money - MSN
InspireMD (NSPR) Q2 2025 Earnings Transcript - AOL.com
InspireMD (NSPR) Q3 2025 Earnings Transcript - AOL.com
Insider Buying: InspireMD (NYSE:NSPR) Director Acquires 15,995 Shares of Stock - MarketBeat
Insider Buying: InspireMD (NYSE:NSPR) Director Acquires 73,255 Shares of Stock - MarketBeat
InspireMD director Ward R. buys $102,637 in company stock By Investing.com - Investing.com Australia
InspireMD director Gary Roubin buys $106,200 in company stock - Investing.com UK
[Form 4] InspireMD, Inc. Insider Trading Activity - Stock Titan
InspireMD director Ward R. buys $102,637 in company stock - Investing.com
InspireMD director Gary Roubin buys $106,200 in company stock By Investing.com - Investing.com Nigeria
Gary Roubin Buys 90,000 Shares of InspireMD (NYSE:NSPR) Stock - MarketBeat
Director Paul Stuka adds 7,895 InspireMD (NSPR) shares in open‑market buys - Stock Titan
Why InspireMD (NSPR) ability to execute stands out (Underperforming) 2026-05-08Long Setup - newser.com
InspireMD, Inc. (NSPR) reports Q1 loss, tops revenue estimates - MSN
InspireMD, Inc. 1Q 2026: Revenue $3.4M, EPS $(0.16) — 10-Q Summary - TradingView
InspireMD (NASDAQ: NSPR) Q1 2026 growth, recall and going concern - Stock Titan
InspireMD (NSPR) Q4 2025 Earnings Transcript - AOL.com
Number of shareholders of InspireMD Inc. – GETTEX:II2 - TradingView
Stroke device maker InspireMD to webcast May 13 conference talk - Stock Titan
InspireMD to Participate in Upcoming Bank of America Securities 2026 Global Healthcare Conference - marketscreener.com
InspireMD, Inc. (NASDAQ:NSPR) Q1 2026 Earnings Call Transcript - Insider Monkey
InspireMD, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Transcript: InspireMD Q1 2026 Earnings Conference Call - Sahm
InspireMD anticipates FDA approval of original CGuard delivery system in Q3 2026 as it withdraws 2026 revenue guidance - MSN
InspireMD Q1 2026 earnings preview - MSN
NSPR: CGuard® Prime leverages clinical leadership and innovation to capture a growing carotid stenting market - TradingView
Earnings call transcript: InspireMD beats Q1 2026 forecasts but faces operational pause By Investing.com - Investing.com South Africa
InspireMD, Inc. (NSPR) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
NSPR: Q1 revenue up 122% year-over-year; U.S. relaunch expected after FDA approval in Q3 2026 - TradingView
Earnings call transcript: InspireMD beats Q1 2026 forecasts but faces operational pause - Investing.com
InspireMD Inc reports results for the quarter ended March 31Earnings Summary - TradingView
InspireMD (NASDAQ:NSPR) Q1 Beat Fails to Impress as Stock Slides - ChartMill
After a recall, InspireMD says another FDA decision is due in Q3 - Stock Titan
InspireMD (NSPR) doubles Q1 revenue, details recall costs and FDA milestones - Stock Titan
InspireMD Initiates Voluntary U.S. Recall of CGuard Prime 135 cm Carotid Stent Delivery System - marketscreener.com
InspireMD recalls CGuard Prime 135 cm carotid stent delivery system in US - Medical Buyer
InspireMD Says FDA Approved Application to Begin SwitchGuard Neuro Protection System CGUARDIANS III Study - Moomoo
FDA Approves InspireMD's Application to Initiate Study of Neuro Protection System -- Update - Moomoo
NSPR rallies after hours on FDA green light for key stroke-prevention trial despite withdrawn annual guidance - MSN
InspireMD Recalls CGuard Prime Delivery System, Pauses U.S. Launch - TipRanks
InspireMD IncRecall Follows Technical Perf - Moomoo
InspireMD Withdraws Guidance, Recalls CGuard Prime - marketscreener.com
Finanzdaten der InspireMD Inc.-Aktie (NSPR)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.34%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):